Literature DB >> 23026619

Co-infection and clinical impact of human herpesvirus 5 and 6 in liver transplantation.

A M Sampaio1, A C Guardia, A Milan, A N Sasaki, P D Andrade, S H A Bonon, R S B Stucchi, S C Botelho Costa, I F S F Boin.   

Abstract

BACKGROUND: Human herpesvirus (HHV) 5 and 6 remain latent after primary infection and can be reactivated after immunosuppression for organ transplantation. An association between HHV-5 and HHV-6 has been reported in liver transplant patients. The coinfection is associated with clinical manifestations and graft dysfunction.
OBJECTIVE: The aim of this study was to monitor herpesviruses in liver transplant recipients to better understand issues involving coinfection with HHV-5/6 and correlations with acute cellular rejection episodes and bacterial infections.
METHODS: Forty-five adult liver transplant patients of median age 47 years (range, 18-66), gave blood samples and liver biopsies in the first 6 months after their surgeries. Viremia was detected with the use of nested PCR and antigenemia; the Banff classification was used to detect allograft rejection.
RESULTS: IgG positive for HHV-5 was observed in 94% of subjects whose main indication (67%) for transplantation was hepatitis C. Twenty-three (51.1%) displayed cytomeg virus (CMV) infections and 12 (26.7%) HHV-6 infection. There were 6 patients (13.3%) with HHV-5/6 coinfections. Eighteen of the 23 patients had CMV disease, showing a strong correlation between a positive test and CMV disease; 6 displayed an acute cellular rejection episode in the same period (χ(2) = 6.62; P < .03). Four out of 6 patients who displayed coinfections (HHV-5/6) had concomitant bacterial infections; 3/6 experienced graft rejection episodes. During follow-up, 1 patient had HHV-6 infection diagnosed as encephalitis followed by fever on the 24th day after surgery. The median 32 days for HHV-6 detection by nested PCR positivity was shorter than 38 days for HHV-5.
CONCLUSIONS: HHV-5/6-infected patients displayed more allograft rejection episodes, coinfections, and concomitant bacterial infections, besides an higher risk for CMV disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026619     DOI: 10.1016/j.transproceed.2012.07.034

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

Review 1.  Cytomegalovirus infection in liver transplant recipients: updates on clinical management.

Authors:  Jasmine Riviere Marcelin; Elena Beam; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Prospective, comprehensive, and effective viral monitoring in Cuban children undergoing solid organ transplantation.

Authors:  Vivian Kourí; Consuelo Correa; Pedro A Martínez; Lizet Sanchez; Alina Alvarez; Grehete González; César E Silverio; Norma Hondal; Jose Florin; Lourdes Pérez; Diana P Duran; Yardelis Perez; Nancy Cazorla; Dalmaris Gonzalez; Juan C Jaime; Alberto Arencibia; Sandra Sarduy; Lissette Pérez; Yudira Soto; Mabel González; Iliana Alvarez; Elvira Dorticós; Juan J Marchena; Luis Solar; Belsy Acosta; Clara Savón; Ulrich Hengge
Journal:  Springerplus       Date:  2014-05-16

3.  Impact of Human Cytomegalovirus and Human Herpesvirus 6 Infection on the Expression of Factors Associated with Cell Fibrosis and Apoptosis: Clues for Implication in Systemic Sclerosis Development.

Authors:  Maria-Cristina Arcangeletti; Maria D'Accolti; Clara Maccari; Irene Soffritti; Flora De Conto; Carlo Chezzi; Adriana Calderaro; Clodoveo Ferri; Elisabetta Caselli
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

4.  Human herpesvirus-6 and cytomegalovirus DNA in liver donor biopsies and their correlation with HLA matches and acute cellular rejection.

Authors:  Ana Carolina Guardia; Raquel Silveira Bello Stucchi; Arlete Milan; Sandra Cecília Botelho Costa; Ilka de Fátima Santana Ferreira Boin
Journal:  Braz J Infect Dis       Date:  2013-11-22       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.